Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

NCT01599754 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

724

Enrollment

INDUSTRY

Sponsor class

Stopped Primary endpoint did not reach statistical significance

Conditions

Clear Cell Renal Carcinoma

Interventions

DRUG: Axitinib
DRUG: Placebo

Sponsor

SFJ Pharma Ltd. II

Collaborators

[object Object]
[object Object]